Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Denosumab Has Edge on Alendronate for Steroid-Induced Bone Loss

Matthew Phelan  |  Issue: April 2021  |  March 10, 2021

NEW YORK (Reuters Health)—Long-term glucocorticoid users see greater gains in spine bone-mineral density when treated with the monoclonal antibody denosumab vs. oral alendronate, a small clinical trial shows.

The drug also proved superior at lowering bone-turnover markers at 12 months, researchers in Hong Kong report in Bone.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Denosumab may be considered as an alternative first-line therapy in higher risk patients using chronic glucocorticoids and in those who are contraindicated for or intolerant to” bisphosphonates, Dr. Chi Chiu Mok of Tuen Mun Hospital and colleagues write.

“The strength of our study is that this is not a commercially sponsored trial,” he tells Reuters Health by email. “The weakness, of course, is the relatively short follow-up time and the sample size from one center. Yet, we feel that it is important to have data in purely Asian patients.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Previous randomized controlled trials have shown denosumab to be superior to bisphosphonates in postmenopausal women, but there is a lack of data from long-term steroid users, particularly Asians, the researchers note.

To investigate, they recruited 139 patients who were receiving long-term prednisolone therapy (at least 2.5 mg/day for at least one year) to a year-long study. All of the patients, 96% of whom were women, were being treated for autoimmune inflammatory diseases as outpatients at Tuen Mun clinics.

Half were randomly assigned to receive denosumab injections (60 mg every six months) and half to receive oral alendronate (70 mg per week). The alendronate group had a higher number of chronic smokers, but there were no other significant differences between the groups.

The patients’ mean age was 50 years and their mean BMI was 23 kg/m2. At the start of the study, they had been taking prednisolone for a mean of 107 months at a mean daily dose of 5.1 mg.

The majority of the patients (59%) had never been previously treated for osteoporosis, whereas the rest had been taking oral bisphosphonates. With one exception, all the patients were ethnic Chinese.

After 12 months, gains in bone-mineral density (BMD) at the lumbar spine favored denosumab-treated patients (3.5% vs. 2.5%), with significantly higher BMD after adjusting for baseline BMD values, age, sex, osteoporosis risk factors and cumulative prednisolone doses received in one year (P=0.045).

Differences in hip and femoral-neck BMD were not statistically significant between the groups.

Denosumab-treated patients showed significantly greater drops in the levels of serum P1NP (53% vs. 22%) and beta-CTX (57% vs. 5.3%) at the 12-month point.

Page: 1 2 | Single Page
Share: 

Filed under:Drug Updates Tagged with:alendronatebone lossbone mineral density (BMD)denosumabGlucocorticoids

Related Articles

    Diagnosis, Management of Medication-Induced Osteonecrosis of the Bone

    October 13, 2015

    Prior to the widespread use of bisphosphonates for the manage­ment of osteoporosis, multiple myeloma and metastatic cancer to the skeletal system, osteonecrosis of the jawbones was an infrequent condition seen after radiation for oral cancers (osteoradionecrosis) and in chronic odontogenic infections.1 Since the mid-2000s, osteonecrosis of the jawbones has been noted to occur as a…

    Build Up Bone

    June 1, 2007

    Current management of osteoporosis

    Reading Rheum

    March 1, 2007

    Handpicked Reviews of Contemporary Literature

    Denosumab May Work Better Than Risedronate for Steroid-Induced Osteoporosis

    April 26, 2018

    NEW YORK (Reuters Health)—The RANKL inhibitor denosumab is superior to the bisphosphonate risedronate in increasing bone-mineral density (BMD) at the lumbar spine in patients just starting or continuing steroid therapy, according to 12-month results of a 24-month randomized controlled study. “Glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis and increases the risk of…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences